Methylation of the genes for the microRNAs miR-129-2 and miR-9-1, changes in their expression, and activation of their potential target genes in clear cell renal cell carcinoma


Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Только для подписчиков

Аннотация

Methylation of promoter CpG islands and microRNA (miRNA) interactions with mRNAs of target genes are epigenetic mechanisms that play a crucial role in deregulation of gene expression and signaling pathways in tumors. Altered expression of six chromosome 3p genes (RARB(2), SEMA3B, RHOA, GPX1, NKIRAS1, and CHL1) and two miRNA genes (MIR-129-2 and MIR-9-1) was observed in primary clear cell renal cell carcinomas (ccRCCs, 31–48 samples) by RT-PCR and qPCR. Significant downregulation (p < 0.05, Fisher’s exact test) was observed for SEMA3B, NKIRAS1, and CHL1; and differential expression, for the other chromosome 3p and miRNA genes. Methylation-specific PCR with primers to RARB(2), SEMA3B, MIR-129-2, and MIR-9-1 showed that their methylation frequency was significantly (p < 0.05, Fisher’s exact test) elevated in the ccRCC samples. Significant correlations between promoter methylation and expression were confirmed for SEMA3B and observed for the first time for RARB(2), GPX1, and MIR-129-2 in ccRCC (Spearman’s correlation coefficient rs ranging 0.31–0.60, p < 0.05). The MIR-129-2 and RARB(2) methylation frequencies significantly correlated with ccRCC progression. MIR-129-2 methylation correlated with upregulation of RARB(2), RHOA, NKIRAS1, and CHL1 (rs ranging 0.35–0.53, p < 0.05). The findings implicate methylation in regulating RARB(2), SEMA3B, GPX1, and MIR-129-2 and indicate that miR-129-2 and methylation of its gene affect RARB(2), RHOA, NKIRAS1, and CHL1 expression.

Об авторах

I. Pronina

Research Centre of Medical Genetics; Institute of General Pathology and Pathophysiology

Автор, ответственный за переписку.
Email: zolly_sten@mail.ru
Россия, Moscow, 115478; Moscow, 125315

E. Klimov

Biological Faculty, Moscow State University

Email: zolly_sten@mail.ru
Россия, Moscow, 119234

A. Burdennyy

Institute of General Pathology and Pathophysiology; Emanuel Institute of Biochemical Physics

Email: zolly_sten@mail.ru
Россия, Moscow, 125315; Moscow, 119334

E. Beresneva

State Research Institute of Genetics and Selection of Industrial Microorganisms

Email: zolly_sten@mail.ru
Россия, Moscow, 117545

M. Fridman

Vavilov Institute of General Genetics

Email: zolly_sten@mail.ru
Россия, Moscow, 117971

V. Ermilova

Cancer Research Center

Email: zolly_sten@mail.ru
Россия, Moscow, 115478

T. Kazubskaya

Cancer Research Center

Email: zolly_sten@mail.ru
Россия, Moscow, 115478

A. Karpukhin

Research Centre of Medical Genetics

Email: zolly_sten@mail.ru
Россия, Moscow, 115478

E. Braga

Research Centre of Medical Genetics; Institute of General Pathology and Pathophysiology

Email: zolly_sten@mail.ru
Россия, Moscow, 115478; Moscow, 125315

V. Loginov

Research Centre of Medical Genetics; Institute of General Pathology and Pathophysiology

Email: zolly_sten@mail.ru
Россия, Moscow, 115478; Moscow, 125315

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML

© Pleiades Publishing, Inc., 2017

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).